Written by the Nuvirox Research Team
Key Points
- No published clinical trial has tested NAD+ precursors specifically in people with fibromyalgia.
- A related, better-studied condition — Gulf War Illness, which shares mitochondrial and fatigue features with fibromyalgia — has an NR trial currently recruiting, but results aren't available yet.
- Fibromyalgia has evidence-based treatments (specific medications, graded exercise, and CBT) that should be the starting point, not a supplement search.
Short answer: there's no direct clinical trial evidence for NAD+ and fibromyalgia — the closest related human research is in a different, adjacent condition, and it hasn't reported results yet. Fibromyalgia is a genuinely difficult, often dismissed condition to live with, so it's worth being straightforward: the current NAD+ research doesn't reach far enough to make a claim here, one way or the other.
Why fibromyalgia and NAD+ get connected
Fibromyalgia is a chronic pain condition involving widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties, with research pointing to abnormalities in central pain processing (how the nervous system amplifies pain signals) as well as some evidence of mitochondrial dysfunction and oxidative stress in affected tissue. Because NAD+ metabolism sits at the center of mitochondrial energy production and cellular antioxidant defense, it's a scientifically reasonable area of curiosity for researchers studying fibromyalgia and related chronic fatigue conditions — but curiosity and completed trials are two different things.
What has actually been studied — and what hasn't
As of this writing, there is no published trial specifically testing an NAD+ precursor in people diagnosed with fibromyalgia. The closest related human research is a currently recruiting randomized, placebo-controlled trial of nicotinamide riboside (300 mg/day) in Gulf War Illness — a chronic condition affecting some veterans of the 1991 Gulf War that shares real overlap with fibromyalgia, including widespread pain, fatigue, and cognitive symptoms, along with preclinical evidence of bioenergetic (mitochondrial) deficits. That trial's primary objective is to see whether NR raises plasma NAD+ levels in this population — an important first step, but it's still in progress, and results aren't available.
What Exists vs. What Doesn't
| Fibromyalgia-specific NAD+ trial | None published |
| Related condition trial (Gulf War Illness) | Recruiting (NCT05243290), results not yet available |
| Mechanistic rationale | Plausible (mitochondrial dysfunction, oxidative stress), unconfirmed for fibromyalgia specifically |
Why "a related condition has a trial" isn't the same as evidence for fibromyalgia
Gulf War Illness and fibromyalgia share some features, but they aren't the same condition, and they don't necessarily share the same underlying cause or the same response to treatment. It would be premature — and honestly a little misleading — to treat a recruiting trial in a different population as if it were evidence for fibromyalgia today. The right way to think about it: this is a related research thread worth watching, not something to act on yet.
What actually has evidence for fibromyalgia
Several treatments have real randomized trial support for fibromyalgia specifically. Certain medications — including duloxetine, milnacipran, and pregabalin — are FDA-approved specifically for fibromyalgia based on clinical trial evidence. Graded, low-impact exercise (like water-based exercise or gentle aerobic activity, started slowly) has consistent trial support for reducing pain and improving function. Cognitive behavioral therapy has evidence for helping people manage fibromyalgia's impact on daily life, even though it doesn't "cure" the underlying condition. A rheumatologist or pain specialist can help build a plan combining these approaches.
What NAD+ won't do for fibromyalgia right now
Based on the current absence of direct evidence, an NAD+ precursor should not be relied on as a fibromyalgia treatment. That could change if the Gulf War Illness trial or future fibromyalgia-specific research produces meaningful results, but as of now, this isn't where the evidence points.
Why fibromyalgia is often dismissed, and why that matters here
Fibromyalgia has historically been under-recognized and sometimes dismissed by clinicians, in part because there's no single blood test or imaging finding that confirms it — diagnosis relies on a clinical pattern of widespread pain and associated symptoms. That history is worth naming, because it's part of why some people end up searching for supplement-based answers rather than pursuing a formal diagnosis and evidence-based treatment: it can take real persistence to find a doctor who takes the condition seriously. That context doesn't change the evidence for NAD+ specifically, but it's a legitimate reason to specifically seek out a rheumatologist or pain specialist experienced with fibromyalgia, rather than a general practitioner unfamiliar with current diagnostic criteria.
What "central sensitization" means in plain terms
A key concept in current fibromyalgia research is central sensitization — the idea that the nervous system itself becomes amplified, processing normal sensory input as pain even without ongoing tissue damage. This helps explain why fibromyalgia often doesn't show up on standard imaging or blood tests despite being a real, disabling condition: the problem is in how pain signals are processed, not necessarily in a specific damaged tissue. This framework is part of why treatments that work on the nervous system broadly (like duloxetine or pregabalin) tend to have better trial support than treatments aimed at a single tissue or localized inflammation, and it's a useful lens for understanding why a general metabolic supplement, even with a plausible mitochondrial rationale, isn't an obvious match for the dominant model of how fibromyalgia pain actually works.
Frequently asked questions
Is there any human trial data at all connecting NAD+ to fibromyalgia?
No published trial has tested NAD+ precursors in fibromyalgia patients specifically. A related trial in Gulf War Illness — a condition with some symptom overlap — is currently recruiting, but hasn't reported results.
Why do fibromyalgia and Gulf War Illness get grouped together in research?
Both conditions involve widespread pain, fatigue, and cognitive symptoms, and both have research suggesting underlying bioenergetic or mitochondrial abnormalities, which makes them scientifically interesting to study with similar tools — though they remain distinct diagnoses.
What medications are actually approved for fibromyalgia?
Duloxetine, milnacipran, and pregabalin are FDA-approved specifically for fibromyalgia in the US, based on clinical trial evidence. A doctor can discuss which, if any, fits your situation.
Is exercise really recommended for fibromyalgia, given the pain?
Yes, but it needs to be graded and gentle, starting well below what might seem obvious, and increasing very gradually. Water-based exercise is often especially well tolerated. A physical therapist familiar with fibromyalgia can help design an appropriate starting point.
FROM NUVIROX
Why we formulated NAD+ Restore
We built NAD+ Restore for general cellular energy support — not as a fibromyalgia treatment, since direct clinical evidence for that use doesn't exist yet. Each 2-capsule serving delivers 500 mg of Nicotinamide Riboside Chloride, one of the two most-researched NAD+ precursors, within the dose range used in published human trials, alongside 150 mg trans-resveratrol and 50 mg quercetin, polyphenols studied alongside NAD+ pathways for cellular health support. 10 mg of galactomannans from fenugreek is included to support absorption.
Backed by a 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.
Learn more about NAD+ Restore →The bottom line
Fibromyalgia and NAD+ is one of the more honest "not yet" answers in this research area: a reasonable biological rationale, a related trial recruiting in an adjacent condition, and no direct clinical evidence to act on today. Evidence-based fibromyalgia management — specific medications, graded exercise, and CBT — remains the better starting point while this research develops. Related reading: mental fatigue vs. physical fatigue and NAD+ and stress resilience.
References
- Nicotinamide Riboside Clinical Trial for GWI (Gulf War Illness). ClinicalTrials.gov Identifier: NCT05243290. Status: recruiting.
- Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555. PMID: 24737367.
- Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID: 27377815.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.